Boston, MA / January 24, 2013 Facioscapulohumeral muscular dystrophy (FSHD) is a disease most people have never heard of, even though it is one of the most common forms of… Read More »
The FSH Society Answers Questions About the New Gene for FSH Muscular Dystrophy
The FSH Society Answers Questions About the New Gene SMCHD1 for FSH Muscular Dystrophy
Fueled by funding from the FSH Society, an international research team has discovered the genes that cause facioscapulohumeral muscular dystrophy (FSHD), a devastating muscle-wasting disease that affects 500,000 people around… Read More »
GlaxoSmithKline PLC (GSK) announces partnership to develop therapeutics to treat FSHD
GlaxoSmithKline PLC (GSK) announces partnership to develop therapeutics to treat FSHD. The goal of the new agreement is to develop a small-molecule-based medicine to potentially reverse FSHD
Year-End Challenge to Fund the Treatment for FSHD!
Year-End Challenge to Fund the Treatment for FSHD! A group of long-time supporters have come forward to challenge the Society’s members and friends to make gifts to Fund the Treatment… Read More »
Canadian Foundation Launched!
Canadian Foundation Launched! Great news for Canadians who wish to support FSHD research! Canadians can now donate funds directly towards FSHD research — and receive a tax deduction. The FSHD… Read More »